ARHI is downregulated in multiple malignant tumors, including ovarian cancer, breast cancer, lung cancer, prostate cancer, thyroid cancer, pancreatic cancer and glioma [7], and over-expression of ARHI at physiological levels can retard proliferation, reduce motility and enhance cancer cell dormancy [8]. Here, DIRAS3 is linked to prostate carcinoma.